

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Colorectal cancer	PD-1 receptor (PDCD1; PD-1; CD279); programmed cell death 1 ligand 1 (CD274 molecule; PD-L1; B7-H1); hepatitis A virus cellular receptor 2 (HAVCR2; TIM3)	<p>A study in mice suggests that combined inhibition of TIM3 and PD-1 pathways could help treat colorectal cancer. In mice with colon adenocarcinoma cells, an antibody against PD-L1 plus an antibody against TIM3 decreased tumor size compared with either antibody alone. Next steps include developing dual inhibitors of PD-1 and TIM3.</p> <p>SciBX 3(37); doi:10.1038/scibx.2010.1115 Published online Sept. 23, 2010</p>	Patent application filed; available for licensing through the Brigham and Women's Hospital Office of Research Ventures and Licensing	<p>Sakuishi, K. <i>et al. J. Exp. Med.</i>; published online Sept. 6, 2010; doi:10.1084/jem.20100643</p> <p>Contact: Ana C. Anderson, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass. e-mail: aanderson@rics.bwh.harvard.edu</p> <p>Contact: Vijay K. Kuchroo, same affiliation as above e-mail: vkuchroo@rics.bwh.harvard.edu</p>